




# RFP-PD-2013-001

## Intent to Apply (ITA)


A total of 36 eligible ITA forms were received. A breakdown of eligible ITA forms by disease, intervention and development stage is shown below: \*



\*One or more ITA included multiple diseases, interventions and/or development stages in the scope.


## Full Proposal

A total of 25 eligible proposals were received. A breakdown of eligible proposals by disease, intervention and development stage is shown below:




■ Malaria ■ TB ■ Leishmaniasis ■ Chagas disease ■ Trypanosomal diseases ■ Schistosomiasis

## Intervention



■ Drug ■ Vaccine ■ Diagnostics

## Development Stage



■ Pre-clinical ■ Clinical

## Award Notification

The following six projects were awarded funding.

Project Title	Collaboration Partners	Disease	Intervention	Development Stage	Total Amount
Development of recombinant hPIV2 virus vector as a new TB vaccine	1. National Institute of Biomedical Innovation, Health and Nutrition (NIBIOHN) 2. JBL 3. Aeras	TB	Vaccine	Pre-clinical	¥70,000,000
Clinical development of BK-SE36/CpG malaria vaccine	1. RIMD, Osaka University 2. Medical Center for Translational Research, Osaka University 3. Gulu University	Malaria	Vaccine	Clinical Ph 1	¥71,450,000
Optimization of Diversity-Oriented Synthesis (DOS)-derived trypanocidal small molecule ML341 towards investigational new drug status for Chagas disease.	1. Broad Institute 2. Eisai	NTD (Chagas disease)	Drug	Pre-clinical	¥50,000,000
Development of DSM265 as a long acting antimalarial compound	1. MMV 2. Takeda	Malaria	Drug	Clinical Ph 2	¥253,879,600
Development of ELQ300 as a long acting antimalarial	1. MMV 2. Takeda	Malaria	Drug	Pre-clinical	¥21,679,055
Accelerating Development of Vaccines for Malaria Elimination Using a Novel Clinical Target Validation Approach	1. PATH Malaria Vaccine Initiative 2. Ehime University 3. Cell Free Sciences	Malaria	Vaccine	Pre-clinical	¥59,139,656